SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies

doi:10.1111/jebm.12414

. 2020 Nov;13(4):255-260.

doi: 10.1111/jebm.12414. Epub 2020 Oct 14.

SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies

Daniel Melo de Oliveira Campos¹, Umberto Laino Fulco¹, Claudio Bruno Silva de Oliveira², Jonas Ivan Nobre Oliveira¹

Affiliations

¹ Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
² Maria Alice Fernandez Pediatric Hospital, Natal, Rio Grande do Norte, Brazil.

PMID: 33058394
PMCID: PMC7675315
DOI: 10.1111/jebm.12414

SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies

Daniel Melo de Oliveira Campos et al. J Evid Based Med. 2020 Nov.

. 2020 Nov;13(4):255-260.

doi: 10.1111/jebm.12414. Epub 2020 Oct 14.

Authors

Daniel Melo de Oliveira Campos¹, Umberto Laino Fulco¹, Claudio Bruno Silva de Oliveira², Jonas Ivan Nobre Oliveira¹

Affiliations

¹ Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
² Maria Alice Fernandez Pediatric Hospital, Natal, Rio Grande do Norte, Brazil.

PMID: 33058394
PMCID: PMC7675315
DOI: 10.1111/jebm.12414

No abstract available

Keywords: COVID-19; SARS-CoV-2; antiviral drugs; therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Cited by

Emerging role of air pollution and meteorological parameters in COVID-19.
Zhao C, Fang X, Feng Y, Fang X, He J, Pan H. Zhao C, et al. J Evid Based Med. 2021 May;14(2):123-138. doi: 10.1111/jebm.12430. Epub 2021 May 18. J Evid Based Med. 2021. PMID: 34003571 Free PMC article. Review.
A critical appraisal of neurological evidence on paediatric COVID-19 patients. A systematic literature review.
Falsaperla R, Gulisano C, Portale L, Maccarrone A, Ruggieri M. Falsaperla R, et al. Heliyon. 2023 May;9(5):e15630. doi: 10.1016/j.heliyon.2023.e15630. Epub 2023 Apr 18. Heliyon. 2023. PMID: 37124342 Free PMC article. Review.
Clinical severe acute respiratory syndrome coronavirus 2 isolation and antiviral testing.
Mathez G, Cagno V. Mathez G, et al. Antivir Chem Chemother. 2021 Jan-Dec;29:20402066211061063. doi: 10.1177/20402066211061063. Antivir Chem Chemother. 2021. PMID: 34806440 Free PMC article.
Use of Traditional, Complementary and Integrative Medicine During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.
Kim TH, Kang JW, Jeon SR, Ang L, Lee HW, Lee MS. Kim TH, et al. Front Med (Lausanne). 2022 May 9;9:884573. doi: 10.3389/fmed.2022.884573. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35615091 Free PMC article.
SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding mode.
Goike J, Hsieh CL, Horton AP, Gardner EC, Zhou L, Bartzoka F, Wang N, Javanmardi K, Herbert A, Abbassi S, Xie X, Xia H, Shi PY, Renberg R, Segall-Shapiro TH, Terrace CI, Wu W, Shroff R, Byrom M, Ellington AD, Marcotte EM, Musser JM, Kuchipudi SV, Kapur V, Georgiou G, Weaver SC, Dye JM, Boutz DR, McLellan JS, Gollihar JD. Goike J, et al. Commun Biol. 2023 Dec 11;6(1):1250. doi: 10.1038/s42003-023-05649-6. Commun Biol. 2023. PMID: 38082099 Free PMC article.

See all "Cited by" articles

References

1. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID‐19). Drug Discov Therap. 2020;14:58‐60. - PubMed
1. Heymann DL, Shindo N. COVID‐19: what is next for public health? Lancet. 2020;395:542‐545. - PMC - PubMed
1. Fisher D, Heymann D. Q&A: the novel coronavirus outbreak causing COVID‐19. BMC Med. 2020; 18: 57. - PMC - PubMed
1. Basgyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID‐19 pandemic. J Dermatolog Treat. 2020;31:317‐318. - PubMed
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727‐733. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

Finance Code 001./Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID‐19). Drug Discov Therap. 2020;14:58‐60. - PubMed

[2] Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID‐19). Drug Discov Therap. 2020;14:58‐60. - PubMed

[3] Heymann DL, Shindo N. COVID‐19: what is next for public health? Lancet. 2020;395:542‐545. - PMC - PubMed

[4] Heymann DL, Shindo N. COVID‐19: what is next for public health? Lancet. 2020;395:542‐545. - PMC - PubMed

[5] Fisher D, Heymann D. Q&A: the novel coronavirus outbreak causing COVID‐19. BMC Med. 2020; 18: 57. - PMC - PubMed

[6] Fisher D, Heymann D. Q&A: the novel coronavirus outbreak causing COVID‐19. BMC Med. 2020; 18: 57. - PMC - PubMed

[7] Basgyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID‐19 pandemic. J Dermatolog Treat. 2020;31:317‐318. - PubMed

[8] Basgyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID‐19 pandemic. J Dermatolog Treat. 2020;31:317‐318. - PubMed

[9] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727‐733. - PMC - PubMed

[10] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727‐733. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies

Affiliations

SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous